open access

Vol 20, No 6 (2015)
Special Issue Papers
Published online: 2015-11-01
Submitted: 2014-07-09
Get Citation

Liver metastases and SBRT: A new paradigm?

Tiziana Comito, Elena Clerici, Angelo Tozzi, Giuseppe D’Agostino
DOI: 10.1016/j.rpor.2014.10.002
·
Rep Pract Oncol Radiother 2015;20(6):464-471.

open access

Vol 20, No 6 (2015)
Special Issue Papers
Published online: 2015-11-01
Submitted: 2014-07-09

Abstract

Background

The outstanding innovations made by early diagnosis, novel surgical techniques, effective chemotherapy regimens and conformal radiotherapy, have significantly improved patients overall survival and quality of life. Multidisciplinary approach to cancer has also led to an increased prevalence of patients with few, organ-confined metastases, who can experience long-term survival even if their disease is no longer localized. Liver is one of the most common site for metastatic disease from several cancers, and when metastatic disease is confined to liver, given the ability of this organ to regenerate almost to its optimal volume, surgical resection represents the standard of care because is associated with a better prognosis. Approximately 70–90% of liver metastases, however, are unresectable and a safe, effective alternative therapeutic option is necessary for these patients.

Materials and methods

A review of the current literature was performed to analyze the role of SBRT in treating liver metastases from different cancers. A literature search using the terms “SBRT” and “liver metastases” was carried out in PUBMED.

Results

Stereotactic body radiation therapy has shown to provide promising results in the treatment of liver metastases, thanks to the ability of this procedure to deliver a conformal high dose of radiation to the target lesion and a minimal dose to surrounding critical tissues.

Conclusion

Stereotactic body radiation therapy is a non-invasive, well-tolerated and effective treatment for patients with liver metastases not suitable for surgical resection.

Abstract

Background

The outstanding innovations made by early diagnosis, novel surgical techniques, effective chemotherapy regimens and conformal radiotherapy, have significantly improved patients overall survival and quality of life. Multidisciplinary approach to cancer has also led to an increased prevalence of patients with few, organ-confined metastases, who can experience long-term survival even if their disease is no longer localized. Liver is one of the most common site for metastatic disease from several cancers, and when metastatic disease is confined to liver, given the ability of this organ to regenerate almost to its optimal volume, surgical resection represents the standard of care because is associated with a better prognosis. Approximately 70–90% of liver metastases, however, are unresectable and a safe, effective alternative therapeutic option is necessary for these patients.

Materials and methods

A review of the current literature was performed to analyze the role of SBRT in treating liver metastases from different cancers. A literature search using the terms “SBRT” and “liver metastases” was carried out in PUBMED.

Results

Stereotactic body radiation therapy has shown to provide promising results in the treatment of liver metastases, thanks to the ability of this procedure to deliver a conformal high dose of radiation to the target lesion and a minimal dose to surrounding critical tissues.

Conclusion

Stereotactic body radiation therapy is a non-invasive, well-tolerated and effective treatment for patients with liver metastases not suitable for surgical resection.

Get Citation

Keywords

SBRT; Liver; Oligometastatic patients

About this article
Title

Liver metastases and SBRT: A new paradigm?

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 20, No 6 (2015)

Pages

464-471

Published online

2015-11-01

DOI

10.1016/j.rpor.2014.10.002

Bibliographic record

Rep Pract Oncol Radiother 2015;20(6):464-471.

Keywords

SBRT
Liver
Oligometastatic patients

Authors

Tiziana Comito
Elena Clerici
Angelo Tozzi
Giuseppe D’Agostino

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl